Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma 29Hodgkin Disease 20Central Nervous System Neoplasms 16Astrocytoma 11Oligodendroglioma 10Glioblastoma 9Brain Neoplasms 9Gliosarcoma 7Glioma 6Recurrence 5Lymphoma, Non-Hodgkin 4Neurotoxicity Syndromes 3Lymphoma, Follicular 3Lymphoma, Mantle-Cell 2Lymphoma, AIDS-Related 2Radiation Injuries 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Optic Nerve Glioma 1Medulloblastoma 1Lymphoma, Large-Cell, Immunoblastic 1Lymphoma, Large B-Cell, Diffuse 1Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8 1Intraocular Lymphoma 1HIV Infections 1Familial ependymoma 1Ependymoma 1Drug-Related Side Effects and Adverse Reactions 1Burkitt Lymphoma 1Ataxia Telangiectasia 1Ataxia 1

Interventions

Radiotherapy 29Cisplatin 12Amifostine 11Radiotherapy, Intensity-Modulated 7Paclitaxel 7Carboplatin 7Etoposide 5Radiosurgery 4Donepezil 4Brachytherapy 4Bevacizumab 4sargramostim 3Surgical Procedures, Operative 3Mental Status and Dementia Tests 3Filgrastim 3Diet Therapy 3Blood Specimen Collection 3Radiation Dose Hypofractionation 2Radiation 2Proton Therapy 2Magnetic Resonance Spectroscopy 2Low-Level Light Therapy 2Lithium 2Hyperbaric Oxygenation 2Heavy Ion Radiotherapy 2Fluorouracil 2Fibroblast Growth Factor 7 2Dexamethasone 2Chemotherapy, Adjuvant 2Androgen Antagonists 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Radiation Injuries × Procarbazine × Clear all
NCT01399372 2023-07-20

Rituximab, Methotrexate, Vincristine Sulfate, Procarbazine Hydrochloride, and Cytarabine With or Without Radiation Therapy in Treating Patients With Primary Central Nervous System Lymphoma

Radiation Therapy Oncology Group

Phase 2 Completed
91 enrolled 17 charts
Lymphoid

Lymphoma, Radiation Injuries, Neurotoxicity Syndromes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡